Ara Dikranian

1.7k total citations · 1 hit paper
18 papers, 917 citations indexed

About

Ara Dikranian is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Ara Dikranian has authored 18 papers receiving a total of 917 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 6 papers in Hematology and 5 papers in Genetics. Recurrent topics in Ara Dikranian's work include Rheumatoid Arthritis Research and Therapies (14 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Ara Dikranian is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Ara Dikranian collaborates with scholars based in United States, Canada and United Kingdom. Ara Dikranian's co-authors include Arthur Kavanaugh, Ronald van Vollenhoven, David Musselman, Cem Gabay, Paul Emery, Micki Klearman, Sunil Agarwal, Karel Pavelká, Jennifer Green and Rieke Alten and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Ara Dikranian

17 papers receiving 888 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

2013 502 citations Cem Gabay, Paul Emery et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ara Dikranian United States	8	582	348	305	192	134	18	917
Yihan Li United States	13	961 1.7×	404 1.2×	536 1.8×	203 1.1×	247 1.8×	34	1.3k
Marek Krogulec United States	6	493 0.8×	194 0.6×	244 0.8×	160 0.8×	134 1.0×	10	675
Kahaku Emoto Japan	6	590 1.0×	167 0.5×	293 1.0×	194 1.0×	182 1.4×	9	827
Jan Brzezicki Poland	8	619 1.1×	425 1.2×	252 0.8×	129 0.7×	54 0.4×	12	909
Oscar G. Segurado United States	17	455 0.8×	412 1.2×	229 0.8×	67 0.3×	158 1.2×	43	1.1k
Maria Silk United States	10	576 1.0×	376 1.1×	79 0.3×	85 0.4×	218 1.6×	18	884
Liliana Morales Argentina	2	469 0.8×	134 0.4×	236 0.8×	141 0.7×	144 1.1×	2	625
A. Friedman United States	9	621 1.1×	337 1.0×	94 0.3×	43 0.2×	41 0.3×	25	743
Jocelyn H. Leu United States	17	612 1.1×	553 1.6×	376 1.2×	78 0.4×	42 0.3×	45	1.1k
Bozena Möller Sweden	9	678 1.2×	471 1.4×	72 0.2×	60 0.3×	203 1.5×	12	962

Countries citing papers authored by Ara Dikranian

Since Specialization

Citations

This map shows the geographic impact of Ara Dikranian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ara Dikranian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ara Dikranian more than expected).

Fields of papers citing papers by Ara Dikranian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ara Dikranian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ara Dikranian. The network helps show where Ara Dikranian may publish in the future.

Co-authorship network of co-authors of Ara Dikranian

This figure shows the co-authorship network connecting the top 25 collaborators of Ara Dikranian. A scholar is included among the top collaborators of Ara Dikranian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ara Dikranian. Ara Dikranian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Baker, Joshua F., Catherine Bakewell, Ara Dikranian, et al.. (2024). Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting. Rheumatology and Therapy. 11(3). 841–853. 1 indexed citations

Baker, Matthew, Sarah Kavanagh, Stanley Cohen, et al.. (2023). A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis & Rheumatology. 75(12). 2107–2115. 14 indexed citations

Dikranian, Ara, Cassandra Calabrese, Clifton O. Bingham, et al.. (2023). AB0705 LONG TERM SAFETY OF CONVENTIONAL AND BIOLOGIC IL-6RI IMMUNOMODULATORS AS SECOND-LINE (2L) OR THIRD-LINE (3L) TREATMENT OF POLYMYALGIA RHEUMATICA. 1556–1557. 1 indexed citations

Dikranian, Ara, Miguel Á. González‐Gay, José María Álvaro‐Gracia, et al.. (2022). Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 8(1). e002103–e002103. 18 indexed citations

Dikranian, Ara, David Gold, Louis Bessette, et al.. (2021). Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatology and Therapy. 9(2). 411–433. 2 indexed citations

Dikranian, Ara, J. Wollenhaupt, Valderílio Feijó Azevedo, et al.. (2019). AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. Annals of the Rheumatic Diseases. 78. 1690–1691. 1 indexed citations

Galloway, James, Ara Dikranian, Cheryl Koehn, et al.. (2019). AB0247 INSIGHTS INTO ADHERENCE AND PATIENT-INITIATED MONOTHERAPY FOR RHEUMATOID ARTHRITIS VIA A GLOBAL SURVEY OF PATIENTS, CAREGIVERS AND PHYSICIANS. Annals of the Rheumatic Diseases. 78. 1580–1581.

Dikranian, Ara, Valderílio Feijó Azevedo, Louis Bessette, et al.. (2018). FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. JCR Journal of Clinical Rheumatology. 25. 1 indexed citations

Gottlieb, Alice B., Jordi Gratacós, Ara Dikranian, et al.. (2018). Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatology International. 39(1). 121–130. 20 indexed citations

10.

Strand, Vibeke, Eun Bong Lee, Yusuf Yazıcı, et al.. (2018). Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clinical Rheumatology. 37(8). 2043–2053. 7 indexed citations

11.

Gibofsky, Allan, James Galloway, Joern Kekow, et al.. (2018). Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. Health and Quality of Life Outcomes. 16(1). 211–211. 30 indexed citations

12.

Dikranian, Ara, Miguel Á. González‐Gay, Liza Takiya, et al.. (2018). SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index. Annals of the Rheumatic Diseases. 77. 925–926. 3 indexed citations

13.

Dikranian, Ara, et al.. (2017). Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study. Rheumatology and Therapy. 4(2). 363–374. 1 indexed citations

14.

Koehn, Cheryl, et al.. (2016). OP0248-PARE Understanding The Importance of A Patient's Role in The Management of Ra: Results from A Patient-Based Survey Developed by The Ra Narrative Global Advisory Panel. Annals of the Rheumatic Diseases. 75. 152–152. 2 indexed citations

15.

Lamba, M., D.E. Furst, Ara Dikranian, et al.. (2016). Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib. Clinical Pharmacology & Therapeutics. 101(6). 745–753. 31 indexed citations

16.

Gabay, Cem, Paul Emery, Ronald van Vollenhoven, et al.. (2013). Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. The Lancet. 381(9877). 1541–1550. 502 indexed citations breakdown →

17.

Gabay, Cem, Paul Emery, Ronald van Vollenhoven, et al.. (2012). LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial. Annals of the Rheumatic Diseases. 71. 152–152. 16 indexed citations

18.

Weinblatt, Michael E., Arthur Kavanaugh, Rubén Burgos‐Vargas, et al.. (2008). Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 58(11). 3309–3318. 267 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact